摘要
目的探究托法替布联合甲氨蝶呤治疗类风湿关节炎(RA)对白细胞介素-2(IL-2)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)、γ干扰素(IFN-γ)的影响。方法选取2020年7月至2022年8月赣南医科大学第一附属医院门诊及住院的80例RA患者作为研究对象,采用随机数字表法分为对照组和治疗组,每组各40例。对照组患者口服甲氨蝶呤治疗,治疗组在对照组方法的基础上联合托法替布治疗。比较两组的治疗效果、疾病相关指标(晨僵持续时间、休息痛、关节肿胀数、关节压痛数)、健康评估问卷(HAQ)评分、28个关节疾病活动度(DAS28)评分、实验室血清学指标[红细胞沉降率(ESR)、C反应蛋白(CRP)、IL-2、IL-6、IL-10、TNF-α、IFN-γ]水平。结果治疗组的临床疗效优于对照组,差异有统计学意义(P<0.05)。治疗后,治疗组晨僵持续时间短于对照组,休息痛评分、HAQ评分、DAS28评分均低于对照组,关节肿胀数、关节压痛数少于对照组,差异有统计学意义(P<0.05)。治疗组治疗后ESR、CRP、IL-2、IL-6、TNF-α、IFN-γ水平均低于对照组,IL-10水平高于对照组,差异有统计学意义(P<0.05)。结论托法替布联合甲氨蝶呤在RA患者治疗中能够有效缓解病情,减轻关节肿痛、压痛、休息痛等临床症状,抑制机体炎症反应,疗效显著,值得推广应用。
Objective To investigate the effect of Tofacitinib combined with Methotrexate on interleukin-2(IL-2),interleukin-6(IL-6),interleukin-10(IL-10),tumor necrosis factor-α(TNF-α)and interferon-γ(IFN-γ)in the treatment of rheumatoid arthritis(RA).Methods A total of 80 RA patients from the First Affiliated Hospital of Gannan Medical University from July 2020 to August 2022 were selected as the research objects,and they were divided into control group and treatment group by random number table method,with 40 cases in each group.The control group was treated with oral Methotrexate,and the treatment group was treated with Tofacitinib on the basis of the control group.The therapeutic effect,disease-related indexes(duration of morning stiffness,rest pain,number of joint swelling,number of joint tenderness),health assessment questionnaire(HAQ)score,disease activity score in 28 joints(DAS28)score,laboratory serological indexes(erythrocyte sedimentation rate[ESR],C-reactive protein[CRP],IL-2,IL-6,IL-10,TNF-α,IFN-γ)levels were compared between the two groups.Results The clinical efficacy of the treatment group was better than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the duration of morning stiffness in the treatment group was shorter than that in the control group,rest pain score,HAQ score and DAS28 score were lower than those in the control group,and the number of joint swelling and joint tenderness in the treatment group were less than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of ESR,CRP,IL-2,IL-6,TNF-α,IFN-γ in the treatment group were lower than those in the control group,while the level of IL-10 was higher than that in the control group,and the differences were statistically significant(P<0.05).Conclusion Tofacitinib combined with Methotrexate in the treatment of RA patients can effectively relieve the disease,reduce joint swelling and pain,tenderness,rest pain and other clinical symptoms,inhibit the body's inflammatory response,and the curative effect is significant.It is worthy of promotion and application.
作者
李荣平
陈琥
谷晓晶
LI Rongping;CHEN Hu;GU Xiaojing(Department of Rheumatology,the First Affiliated Hospital of Gannan Medical University,Jiangxi Province,Ganzhou 341001,China)
出处
《中国当代医药》
2025年第21期37-40,共4页
China Modern Medicine
基金
江西省卫生健康委科技计划项目(202130681)。
作者简介
李荣平,男,硕士,研究方向:风湿免疫临床医学。
